Actinium announces positive interim results of antibody-radionuclide conjugate Iomab-B pivotal trial
New York, USA, Monday, October 28, 2019 - Actinium Pharmaceuticals Inc. announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, an antibody-radionuclide conjugate, including feasibility and [...]